These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22508685)

  • 1. Enteropathogenic viruses: triggers for exacerbation in IBD? A prospective cohort study using real-time quantitative polymerase chain reaction.
    Masclee GM; Penders J; Pierik M; Wolffs P; Jonkers D
    Inflamm Bowel Dis; 2013 Jan; 19(1):124-31. PubMed ID: 22508685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is clostridium difficile associated with relapse of inflammatory bowel disease? results from a retrospective and prospective cohort study in the Netherlands.
    Masclee GM; Penders J; Jonkers DM; Wolffs PF; Pierik MJ
    Inflamm Bowel Dis; 2013 Sep; 19(10):2125-31. PubMed ID: 23867869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enteric viral pathogens in children with inflammatory bowel disease.
    Kolho KL; Klemola P; Simonen-Tikka ML; Ollonen ML; Roivainen M
    J Med Virol; 2012 Feb; 84(2):345-7. PubMed ID: 22170557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal excretion of alpha 2-macroglobulin: a novel marker for disease activity in patients with inflammatory bowel disease.
    Becker K; Niederau C; Frieling T
    Z Gastroenterol; 1999 Jul; 37(7):597-605. PubMed ID: 10458008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
    García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
    J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
    Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
    Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
    Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
    Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.
    Sipeki N; Davida L; Palyu E; Altorjay I; Harsfalvi J; Szalmas PA; Szabo Z; Veres G; Shums Z; Norman GL; Lakatos PL; Papp M
    World J Gastroenterol; 2015 Jun; 21(22):6952-64. PubMed ID: 26078573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enteric Viruses and Inflammatory Bowel Disease.
    Tarris G; de Rougemont A; Charkaoui M; Michiels C; Martin L; Belliot G
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33451106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora.
    Swidsinski A; Loening-Baucke V; Vaneechoutte M; Doerffel Y
    Inflamm Bowel Dis; 2008 Feb; 14(2):147-61. PubMed ID: 18050295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal observation of enterovirus and adenovirus in stool samples from Norwegian infants with the highest genetic risk of type 1 diabetes.
    Cinek O; Witsø E; Jeansson S; Rasmussen T; Drevinek P; Wetlesen T; Vavrinec J; Grinde B; Rønningen KS
    J Clin Virol; 2006 Jan; 35(1):33-40. PubMed ID: 15916916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
    Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective, case-control study on traditional environmental risk factors in inflammatory bowel disease in Vukovar-Srijem County, north-eastern Croatia, 2010.
    Vcev A; Pezerovic D; Jovanovic Z; Nakic D; Vcev I; Majnarić L
    Wien Klin Wochenschr; 2015 May; 127(9-10):345-54. PubMed ID: 25821054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Nonsteroidal Anti-Inflammatory Drugs in Exacerbations of Inflammatory Bowel Disease.
    Long MD; Kappelman MD; Martin CF; Chen W; Anton K; Sandler RS
    J Clin Gastroenterol; 2016 Feb; 50(2):152-6. PubMed ID: 26485106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificities of the fecal microbiota in inflammatory bowel disease.
    Sokol H; Seksik P; Rigottier-Gois L; Lay C; Lepage P; Podglajen I; Marteau P; Doré J
    Inflamm Bowel Dis; 2006 Feb; 12(2):106-11. PubMed ID: 16432374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma intestinal fatty acid-binding protein fails to predict endoscopic disease activity in inflammatory bowel disease patients.
    Bodelier AG; Pierik MJ; Lenaerts K; de Boer E; Olde Damink SW; Hameeteman WM; Masclee AA; Jonkers DM
    Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):807-13. PubMed ID: 26919325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual fecal alpha 1-antitrypsin excretion reflects clinical activity in Crohn's disease but not in ulcerative colitis.
    Becker K; Berger M; Niederau C; Frieling T
    Hepatogastroenterology; 1999; 46(28):2309-14. PubMed ID: 10521988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study).
    Henriksen M; Jahnsen J; Lygren I; Sauar J; Schulz T; Stray N; Vatn MH; Moum B;
    Scand J Gastroenterol; 2006 Sep; 41(9):1037-43. PubMed ID: 16938716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.